AU2016209200B2 - 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM) - Google Patents

4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM) Download PDF

Info

Publication number
AU2016209200B2
AU2016209200B2 AU2016209200A AU2016209200A AU2016209200B2 AU 2016209200 B2 AU2016209200 B2 AU 2016209200B2 AU 2016209200 A AU2016209200 A AU 2016209200A AU 2016209200 A AU2016209200 A AU 2016209200A AU 2016209200 B2 AU2016209200 B2 AU 2016209200B2
Authority
AU
Australia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
piperidine
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016209200A
Other languages
English (en)
Other versions
AU2016209200A1 (en
Inventor
Danielle Aubele
Jae Kim
Robert Mcdowell
Johan Oslob
Yonghong Song
Arvinder Sran
Min Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of AU2016209200A1 publication Critical patent/AU2016209200A1/en
Application granted granted Critical
Publication of AU2016209200B2 publication Critical patent/AU2016209200B2/en
Priority to AU2020244490A priority Critical patent/AU2020244490B2/en
Priority to AU2023200361A priority patent/AU2023200361B2/en
Priority to AU2024266781A priority patent/AU2024266781A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016209200A 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM) Active AU2016209200B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020244490A AU2020244490B2 (en) 2015-01-22 2020-09-30 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2023200361A AU2023200361B2 (en) 2015-01-22 2023-01-24 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2024266781A AU2024266781A1 (en) 2015-01-22 2024-11-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562106571P 2015-01-22 2015-01-22
US62/106,571 2015-01-22
PCT/US2016/014365 WO2016118774A1 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020244490A Division AU2020244490B2 (en) 2015-01-22 2020-09-30 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Publications (2)

Publication Number Publication Date
AU2016209200A1 AU2016209200A1 (en) 2017-08-10
AU2016209200B2 true AU2016209200B2 (en) 2020-07-02

Family

ID=55275230

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2016209200A Active AU2016209200B2 (en) 2015-01-22 2016-01-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2020244490A Active AU2020244490B2 (en) 2015-01-22 2020-09-30 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2023200361A Active AU2023200361B2 (en) 2015-01-22 2023-01-24 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2024266781A Pending AU2024266781A1 (en) 2015-01-22 2024-11-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020244490A Active AU2020244490B2 (en) 2015-01-22 2020-09-30 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2023200361A Active AU2023200361B2 (en) 2015-01-22 2023-01-24 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2024266781A Pending AU2024266781A1 (en) 2015-01-22 2024-11-21 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)

Country Status (36)

Country Link
US (1) US9925177B2 (enExample)
EP (2) EP4234017A3 (enExample)
JP (1) JP6712275B2 (enExample)
KR (3) KR20240119163A (enExample)
CN (3) CN118164961A (enExample)
AU (4) AU2016209200B2 (enExample)
BR (1) BR112017015627B1 (enExample)
CA (1) CA2974370C (enExample)
CL (1) CL2017001871A1 (enExample)
CO (1) CO2017008398A2 (enExample)
CR (1) CR20170370A (enExample)
DK (1) DK3247707T3 (enExample)
DO (2) DOP2017000166A (enExample)
EA (1) EA036923B1 (enExample)
EC (1) ECSP17054181A (enExample)
ES (1) ES2953480T3 (enExample)
FI (1) FI3247707T3 (enExample)
GT (1) GT201700163A (enExample)
HR (1) HRP20230737T1 (enExample)
HU (1) HUE063410T2 (enExample)
IL (6) IL295547A (enExample)
LT (1) LT3247707T (enExample)
MX (3) MX2022007040A (enExample)
MY (1) MY203427A (enExample)
PE (2) PE20212253A1 (enExample)
PH (2) PH12017501279B1 (enExample)
PL (1) PL3247707T3 (enExample)
PT (1) PT3247707T (enExample)
RS (1) RS64432B1 (enExample)
SG (2) SG11201705928XA (enExample)
SI (1) SI3247707T1 (enExample)
SM (1) SMT202300259T1 (enExample)
TN (1) TN2017000320A1 (enExample)
UA (1) UA119905C2 (enExample)
WO (1) WO2016118774A1 (enExample)
ZA (1) ZA201704777B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
MA50173A (fr) 2017-09-13 2020-07-29 Amgen Inc Composés activateurs de bisamide sarcomère et leurs utilisations
MX2020007532A (es) 2018-01-19 2020-09-09 Cytokinetics Inc Inhibidores de sarcomero cardiaco.
IL276410B2 (en) 2018-02-01 2024-09-01 Myokardia Inc Pyrazole compounds and preparation thereof
JP7610985B2 (ja) 2018-06-26 2025-01-09 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
US11964967B2 (en) 2018-06-26 2024-04-23 Cytokinetics, Inc. Cardiac sarcomere inhibitors
GB201813312D0 (en) 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
CN118955409A (zh) 2018-08-31 2024-11-15 赛特凯恩蒂克公司 心脏肌小节抑制剂
GB201905520D0 (en) 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use
CA3138080A1 (en) * 2019-05-19 2020-11-26 Jean-Francois TAMBY Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl) n-(isoxazol-3-yl)piperidine-1-carboxamid
TW202116765A (zh) 2019-07-16 2021-05-01 美商邁奧卡迪亞公司 (r)-4-(1-((3-(二氟甲基)-1-甲基-1h-吡唑-4-基)磺醯基)-1-氟乙基)-n-(異噁唑-3-基)哌啶-1-甲醯胺之多晶型物形式
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
PE20230608A1 (es) 2020-05-05 2023-04-13 Nuvalent Inc Quimioterapicos de eter macrociclico heteroaromatico
EP4146205A4 (en) 2020-05-05 2024-05-29 Nuvalent, Inc. HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS
BR112022025551A2 (pt) * 2020-06-15 2023-03-07 Myokardia Inc Tratamento de disfunção atrial
KR102541297B1 (ko) 2020-08-18 2023-06-09 가톨릭대학교 산학협력단 확장성 심근병 모델 및 이의 제조방법
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤
CN118234725A (zh) 2021-10-01 2024-06-21 纽威伦特公司 杂芳族大环醚化合物的固体形式、药物组合物及制备
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
WO2025244956A1 (en) 2024-05-20 2025-11-27 MyoKardia, Inc. Methods of manufacturing danicamtiv

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US20100113377A1 (en) * 2008-10-31 2010-05-06 Simpson Paul C Method of Treatment Using Alpha-1-Adrenergic Agonist Compounds
EP2500345A1 (en) * 2009-11-11 2012-09-19 Dainippon Sumitomo Pharma Co., Ltd. 8-azabicyclo[3.2.1]octane-8-carboxamide derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53600B1 (sr) * 2004-06-17 2015-02-27 Cytokinetics, Inc. Jedinjenja, preparati i metode
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
WO2009011850A2 (en) * 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
US20100113377A1 (en) * 2008-10-31 2010-05-06 Simpson Paul C Method of Treatment Using Alpha-1-Adrenergic Agonist Compounds
EP2500345A1 (en) * 2009-11-11 2012-09-19 Dainippon Sumitomo Pharma Co., Ltd. 8-azabicyclo[3.2.1]octane-8-carboxamide derivative

Also Published As

Publication number Publication date
IL271034A (en) 2020-01-30
BR112017015627B1 (pt) 2022-11-16
WO2016118774A1 (en) 2016-07-28
UA119905C2 (uk) 2019-08-27
SG11201705928XA (en) 2017-08-30
DK3247707T3 (da) 2023-07-03
IL295547A (en) 2022-10-01
ES2953480T3 (es) 2023-11-13
TN2017000320A1 (en) 2019-01-16
KR102688851B1 (ko) 2024-07-29
AU2024266781A1 (en) 2024-12-12
PL3247707T3 (pl) 2023-12-11
AU2023200361A1 (en) 2023-02-23
AU2023200361B2 (en) 2024-08-22
RS64432B1 (sr) 2023-09-29
AU2020244490A1 (en) 2020-10-29
KR102585550B1 (ko) 2023-10-10
EA036923B1 (ru) 2021-01-15
MX394704B (es) 2025-03-24
PH12021553074A1 (en) 2023-03-06
IL253552B (en) 2019-12-31
LT3247707T (lt) 2023-08-25
JP6712275B2 (ja) 2020-06-17
DOP2022000172A (es) 2022-09-30
DOP2017000166A (es) 2017-10-15
AU2020244490B2 (en) 2022-12-01
SMT202300259T1 (it) 2023-09-06
CA2974370A1 (en) 2016-07-28
HUE063410T2 (hu) 2024-01-28
SI3247707T1 (sl) 2023-10-30
EP4234017A2 (en) 2023-08-30
EP3247707A1 (en) 2017-11-29
BR112017015627A2 (pt) 2018-03-13
MX2021010778A (es) 2022-08-11
EP4234017A3 (en) 2023-10-18
SG10201913047UA (en) 2020-02-27
KR20240119163A (ko) 2024-08-06
US9925177B2 (en) 2018-03-27
IL313678A (en) 2024-08-01
IL253552A0 (en) 2017-09-28
PH12017501279B1 (en) 2023-06-16
CR20170370A (es) 2017-10-20
EA201791656A1 (ru) 2017-11-30
JP2018502883A (ja) 2018-02-01
PE20212253A1 (es) 2021-11-24
MX2017009540A (es) 2017-10-20
CN107428719A (zh) 2017-12-01
MX385960B (es) 2025-03-18
CL2017001871A1 (es) 2018-04-13
MX2022007040A (es) 2022-06-24
MY203427A (en) 2024-06-27
CN111393414B (zh) 2024-05-07
GT201700163A (es) 2018-10-18
US20160243100A1 (en) 2016-08-25
CN118164961A (zh) 2024-06-11
IL279247A (en) 2021-01-31
PH12017501279A1 (en) 2018-01-29
IL286369A (en) 2021-10-31
FI3247707T3 (fi) 2023-08-22
CN111393414A (zh) 2020-07-10
KR20230145504A (ko) 2023-10-17
ECSP17054181A (es) 2019-02-28
NZ734020A (en) 2023-11-24
AU2016209200A1 (en) 2017-08-10
CA2974370C (en) 2023-10-31
CN107428719B (zh) 2020-03-27
CO2017008398A2 (es) 2017-10-31
EP3247707B1 (en) 2023-05-31
PE20171511A1 (es) 2017-10-20
PT3247707T (pt) 2023-08-31
HK1246775A1 (en) 2018-09-14
HRP20230737T1 (hr) 2023-10-13
ZA201704777B (en) 2023-07-26
KR20170113578A (ko) 2017-10-12

Similar Documents

Publication Publication Date Title
AU2020244490B2 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
AU2018291688B2 (en) Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections
CA3231743A1 (en) Pyridinylacetamide derivatives as sodium channel activators
US20250275952A1 (en) 4-methylsulfonyl-substituted piperidine urea compounds
HK40100462A (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
HK1246775B (en) 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm)
CA3137152A1 (en) Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a] pyridine derivatives and use thereof
NZ772098B2 (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (DCM)
HK40027481A (en) 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
HK40027481B (zh) 用於治疗扩张性心肌病(dcm)的4-甲基磺酰基取代的哌啶脲化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)